New hope for patients with sarcopenic obesity unable to join clinical trials

NCT ID NCT06784297

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: Immunis, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated May 08, 2026 · Updated 11 times

Summary

This program provides expanded access to an experimental treatment called IMM01-STEM for people with sarcopenic obesity—a condition where both muscle loss and excess body fat occur. It is designed for patients who cannot participate in other clinical trials due to eligibility, location, or other reasons. The goal is to offer potential benefit to those who have limited options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

Explore the condition pages connected to this study.